<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404430</url>
  </required_header>
  <id_info>
    <org_study_id>0627</org_study_id>
    <nct_id>NCT00404430</nct_id>
  </id_info>
  <brief_title>Protocol Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Predictive Factors of Endothelial Function in Chronic Obstructive Disease Patients at the End of a Acute Exacerbation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the predictive factors of the endothelial&#xD;
      function to the waning of an acute exacerbation in COPD. It will act to do a multivariate&#xD;
      analysis to determine the respective weight of the parameters of the systemic inflammation,&#xD;
      of the oxidative stress of the functional respiratory parameters and then functional&#xD;
      respiratory parameters.&#xD;
&#xD;
      In exacerbated Chronic Obstructive Pulmonary Disease (COPD) patients, there is augmentation&#xD;
      of hypoxia and the obstructive ventilatory disorders is more important. This is correlated&#xD;
      with an increase in C-reactive Protein (CRP) and of inflammatory cytokines and oxidative&#xD;
      stress. It has been demonstrated that there is an endothelial dysfunction in answer to&#xD;
      hypoxia. Since the exacerbated COPD patients are hypoxic in most cases , we suppose they have&#xD;
      an endothelial dysfunction during exacerbation. So we think we will find an augmentation of&#xD;
      vascular resistances ,shown by a peripheral arterial tone too high. And this, certainly, play&#xD;
      a part in physiopathology of the COPD exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We want to judge the improvement of the endothelial function remotely to the acute&#xD;
      exacerbation (6 weeks). And then we would like to correlate this improvement with the&#xD;
      variations of oxidative stress, muscle strength, respiratory function and systemic&#xD;
      inflammation.&#xD;
&#xD;
      We also would like to find a relation between the new hospitalizations for respiratory&#xD;
      exacerbation and the initial value of endothelial function.&#xD;
&#xD;
      Then we would like to evaluate the relationship between the cardiovascular risk and the COPD&#xD;
      severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>peripheral arterial tone</measure>
    <time_frame>once a year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength measurements</measure>
    <time_frame>once a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological markers of inflammation and oxidative stress</measure>
    <time_frame>once a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function measurements</measure>
    <time_frame>once a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the relationship between the RMI measurements and the cardiovascular risk</measure>
    <time_frame>once during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the relationship between the hospitalizations for decompensation and the initial value of endothelial function</measure>
    <time_frame>study time frame</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the relationship between the RMI measurements and the COPD severity</measure>
    <time_frame>once during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the prevalence of nocturnal non-dipping blood pressure in COPD patients</measure>
    <time_frame>once a year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>pulse wave velocity measurement</measure>
    <time_frame>once a year</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">121</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Exacerbated COPD patients</arm_group_label>
    <description>Patients with exacerbated COPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable COPD patients</arm_group_label>
    <description>Patients with stable COPD</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples for analysis of inflammatory and oxidative biological markers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with exacerbated (50) or stable (195) COPD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD patients with the waning of exacerbation:&#xD;
&#xD;
          -  Male or Female more than 18 years old&#xD;
&#xD;
          -  VEF1/FCV &lt; 70% or COPD already knew&#xD;
&#xD;
          -  At the moment of the respiratory failure, the day of the enter in hospital:&#xD;
&#xD;
          -  Respiratory frequency &gt;25&#xD;
&#xD;
          -  PaCO2 &gt; 45 mmHg&#xD;
&#xD;
          -  pH &lt; 7.35&#xD;
&#xD;
          -  The day of the inclusion in our study:&#xD;
&#xD;
          -  PH &gt; 7.33 at the end of the respiratory failure, or 2 days of continuation, 3 to 7&#xD;
             days post acute exacerbation of continuation&#xD;
&#xD;
          -  Fever &lt; 38.5&#xD;
&#xD;
          -  Patients who have signed the inform consent form&#xD;
&#xD;
          -  Stable COPD patients:&#xD;
&#xD;
          -  Men or women more than 18 years old&#xD;
&#xD;
          -  VEF1/FCV &lt; 70% or COPD already knew&#xD;
&#xD;
          -  Patients who have signed the inform consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evolutive obvious infection or CRP &gt; 100 at inclusion Cardiac failure considered like&#xD;
             the major cause of the exacerbation or cardiac insufficiency with FEVG &lt; 45 %&#xD;
&#xD;
          -  Smoker &gt; 10 cigarettes a day Antioxidant catch: N-acetyl-cystein, selenium, ascorbic&#xD;
             acid, alpha tocopherol acetate…&#xD;
&#xD;
          -  Evolutive neoplasia&#xD;
&#xD;
          -  Antioxidant catch: N-acetyl-cystein, selenium, ascorbic acid, alpha tocopherol&#xD;
             acetate…&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  patient under supervision or trusteeship&#xD;
&#xD;
          -  patient taking part in another clinical trial&#xD;
&#xD;
          -  claustrophobia, patients allergic to contrast agents like Gadolinium, presence of&#xD;
             material dissuading the realization of a MRI (pacemaker, implantable defibrillator,&#xD;
             insulin pump, ferrometallic clips or foreign bodies in brain or eyes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis JP Pépin, ProfessorPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>France : Laboratoire EFCR - Functional Cardio-Respiratory Exploration Laboratory</name>
      <address>
        <city>Grenoble</city>
        <state>Isere</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Malo O, Sauleda J, Busquets X, Miralles C, Agustí AG, Noguera A. [Systemic inflammation during exacerbations of chronic obstructive pulmonary disease]. Arch Bronconeumol. 2002 Apr;38(4):172-6. Spanish.</citation>
    <PMID>11953269</PMID>
  </reference>
  <reference>
    <citation>Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakynthinos S, Roussos C. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1572-8. Epub 2002 Oct 3.</citation>
    <PMID>12406849</PMID>
  </reference>
  <reference>
    <citation>Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006 Jan;61(1):10-6. Epub 2005 Nov 11.</citation>
    <PMID>16284220</PMID>
  </reference>
  <reference>
    <citation>Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, Hussain SN, Gea J. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 May 15;171(10):1116-24. Epub 2005 Feb 25.</citation>
    <PMID>15735057</PMID>
  </reference>
  <reference>
    <citation>Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005 Jan 25;111(3):363-8. Review.</citation>
    <PMID>15668353</PMID>
  </reference>
  <results_reference>
    <citation>Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc. 2005;2(4):361-6; discussion 371-2. Review.</citation>
    <PMID>16267363</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial function</keyword>
  <keyword>Peripheral Arterial Tone</keyword>
  <keyword>Systemic Inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Respiratory and peripheral muscular function</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>COPD severity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

